Clinical Trials

  • The purpose of this study is to find out if the study drug, HE4 has the potential to improve performance of biomarker CA 125 to determine recurrence of epithelial ovarian cancer before detecting the cancer clinically, surgically or through radiological scans. HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. CA 125 is a protein found on the surface of ovarian cancer cells. Study visits will consist of 5 minute blood draws.
  • Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication.
  • Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication.
  • The purpose of this study is to evaluate how accurately cells that are collected from the Fallopian tube can be categorized as benign or malignant. The MAKO 7 will be used to collect cell samples from the Fallopian tube. You are being asked to participate in the study because you are a woman who is undergoing a surgery to remove your Fallopian tubes and/or ovaries due to a suspicious pelvic mass. The MAKO 7 device is designed to collect cells from the Fallopian tube. The MAKO 7 contains a very small balloon, which enters the Fallopian tube.
  • HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals. You are being asked to take part in this study because you have been diagnosed with Primary Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and will be receiving initial treatment for your disease.
  • The purpose of this study is to find out what effects, good or bad, cobimetinib and niraparib, given with or without atezolizumab, have on you and your cancer. In this study, you will receive either cobimetinib plus niraparib or cobimetinib plus niraparib plus atezolizumab. In addition, if you are assigned to receive cobimetinib and niraparib and your cancer progresses, you could receive atezolizumab along with cobimetinib and niraparib if your doctor believes that you may benefit from this treatment.
  • The main purpose of this study is to: Find out if the study vaccine therapies cause any side effects (unexpected or unwanted reactions) and how well they are tolerated in women with persistent HPV types 16 or 18 infection of the cervix. Find out whether your body responds (the immune response). Compare the effects (both good and bad) of the study vaccines to those of the placebo injections. Theplacebo given in this study will consist of saline (sterile salt water) and looks just like the study vaccines and is given the same way, but has no active vaccine in it.
  • Tired of having to remember to take your birth control? If you are a woman between the ages of 18 and 35, are pre-menopausal, sexually active and do NOT wish to become pregnant, you are invited to see if you may qualify for a research study. The purpose of this research study is to test the effectiveness of an investigational contraceptive vaginal ring. If you qualify, you will receive investigational study medication, study-related medical exams, and laboratory services at no charge. You may also be reimbursed for time, travel, and other expenses.
  • Test the safety and effectiveness of the research study drug, pembrolizumab (MK-3475) in combination with chemotherapy, compared to chemotherapy plus placebo (a look-alike drug with no active ingredients) in women with persistent, recurrent, or metastatic cervical cancer. To test if adding pembrolizumab (MK-3475) to standard chemotherapy improves survival women with persistent, recurrent, or metastatic cervical cancer. Pembrolizumab (MK-3475), also called KEYTRUDA has been approved for use in certain types of cancers; however it may not be approved to treat your type of cancer.
  • The main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.

Pages